Valacyclovir
As the patient receives prescribed medication free or pays a fixed fee, in the uk all the savings from parallel trade either pass directly to the government through the clawback or to the pharmacist, if they are able to achieve a level of discount savings greater than that recouped by the clawback.
Buy cheap Valacydlovir online
Participants in Live and Remember in Kyiv asked passers-by to write on a banner about HIV AIDS Ukraine. Theatre, debates, memorial quilts and round table discussions took place in 13 cities under the slogan Live and Remember. The Network distributed thousands of packs of information on the right to free, anonymous testing and on the rights of people living with HIV AIDS. Live and Remember was widely covered by the press and in some cities, an increased number of requests for information and testing followed. As part of the coverage of the memorial day, a phone-in survey on a popular TV breakfast show asked watchers: Can an HIV-positive person be your friend? Fifty-five percent of respondents said they would be afraid to have such a friend. The Network events contributed to changing such popular attitudes to the virus and those affected by it. For more information, contact Vladimir Zhovtyak. Tel. + 380 532 ; 500752 -mail: zhovtyak ukr lgvs .ua, for example, valacyclovir vs acyclovir.
New drugs added since June 2002 indicated in bold. ANTIRETROVIRALS NRTIs- abacavir Ziagen ; , abacavir lamivudine zidovudine Trizivir ; , didanosine ddI, Videx ; , emtricitabine Emtriva ; , lamivudine Epivir, 3TC ; , lamivudine zidovudine Combivir ; , stavudine d4T, Zerit ; , tenofovir Viread ; , zalcitabine ddC, Hivid ; , zidovudine AZT, Retrovir ; . PIs- amprenavir Agenerase ; , atazanavir Reyataz ; , indinavir Crixivan ; , lopinavir ritonavir Kaletra ; , nelfinavir Viracept ; , ritonavir Norvir ; , saquinavir Fortovase, Invirase ; . NNRTIs- delavirdine Rescriptor ; , efavirenz Sustiva ; , nevirapine Viramune ; . Other- hydroxyurea generic ; . Entry Inhibitor- enfuvirtide Fuzeon ; . OI DRUGS PHS "A1 OI"s- acyclovir Zovirax ; , azithromycin Zithromax ; , clarithromycin Biaxin ; , fluconazole Diflucan ; , ganciclovir Cytovene ; , isoniazid, itraconazole Sporonox ; , leucovorin Folinic Acid ; , pyrimethamine, sulfadiazine, TMP SMX Bactrim, Septra ; . Other OIs- atovaquone Mepron ; , ciprofloxacin Cipro ; , dapsone, ethambutol Myambutol ; , pentamidine Nebupent ; , primaquine, rifabutin Mycobutin ; , valacyclovir Valtrex ; , valganciclovir Valcyte ; , Hepatitis C- interferon alfa Intron A ; , peg-interferon alfa-2b & ribavirin Peg-Intron Rebetol ; , peg-interferon alfa-2a & ribavirin Pegasys Copagus ; . ALL OTHERS amitriptyline, citalopram Celexa ; , clonazepam, fentanyl patch Duragesic ; , fluoxetine Prozac ; , lorazepam, gabapentin Neurontin ; , morphine sulfate, olanzapine Zyprexa ; , Oxycondone r-Oxycondone, Oxycontin, paroxetine Paxil ; , risperidone Risperdal ; , Roxycodone, trazodone, sertraline Zoloft ; . Removed in 2003- Oramorph SR.
Posted: wed sep 05, 2007 post subject: valtrex valacyclovir ; is a prodrug of acyclovir, so when it breaks down in your body then it becomes acyclovir and works in exactly the same way.
In November 2003 I chaired a Scientific Meeting of the British Society for Allergy Environmental and Nutritional Medicine at The Royal College of General Practitioners which spent the day discussing the toxicity of mercury amalgam. Up until that day I had been advising patients to remove mercury amalgams when the opportunity arose and replace them with white, gold or ceramic fillings. Since that meeting I have had all my mercury fillings replaced. The evidence presented was so compelling that I now advising all my patients to get rid of their mercury fillings as part of any general work up to almost any health problem, including wishing to live to a ripe old age.
Of course, SARS the word didn't exist yet. What we announced . is that we had, I going by memory here, I don't have any notes on that, is that we had some people who were very seriously ill with pneumonia in a small cluster. At that point I think, we had figured out that mother had been in Hong Kong, the mother who the coroner had put down she had died of a myocardial infarction and there was no autopsy. But that we had a small cluster of atypical pneumonia. That may be what they were seeing in the Far East. And we specifically gave the name of the mother on the press conference, because they felt it was important that anyone who was at her funeral would call us. And we said, "We're setting up a hotline, " this was late Friday night, we said we are setting up a hotline, call Public Health if you were at the funeral, or you've been travelling or if you have any of these symptoms. And of course, there was a huge amount of media coverage the next day and our hotline was up and running and we got a lot of calls right away. One of the calls we got the next day was the family doctor who had seen the mother and now had the symptoms. And at the same time I was calling other directors to start to get staff in because obviously, it was Friday night, we had to get staff in for Saturday to set up a case management team hotline. In the meantime, Public Health continued to try to identify contacts and follow up with each contact to determine if they were symptomatic. The Commission commends Public Health officials for quickly notifying the public of the family cluster of illness. Despite the fact that much remained unknown, the communication with the public was an important step in the containment of the outbreak. As the number of contacts grew, a broad-based approach to contact tracing had to be utilized in conjunction with the ongoing efforts to identify and contact all individuals who might have been exposed to the disease. It is particularly commendable that the T family put the health of others first, allowing Public Health officials to release their names to the public. Without this consent, the decision to release identifying information about the family would have been a much more difficult decision, as the legal power to do so was not entirely clear at the time.125 Although it would appear that such a disclosure might be permitted today and ativan.
Realignment takes the money out of the county's general fund and puts it into a dedicated fund specifically for a health or social service program.
Valacyclovir mechanism
CHAPTER 22: DRUG DELIVERY SYSTEMS specificities for cell surface receptors, each combination is considered to have a different function. The specificity of the binding sites of the lectins suggests that there are endogenous saccharide receptors in the tissues from which they are derived or on other cells or glycoconjugates with which the lectins specifically interact. On the other hand, some lectins are expressed on the surface of human cells and therefore can be used as a target for drug delivery. In vertebrates, two broad classes of lectins have been identified.123 The C-type lectins, such as selectins and pentraxins, require calcium for carbonate binding. The S-type lectins, now known as the galectins, are calcium independent and are found in species ranging from Caenorhabditis elegans to humans. Many lectins are expressed in a few normal tissues e.g., colon ; and are overexpressed in many cancer cells.124 Therefore, both lectins and carbohydrates can be used as targeting moieties to carbohydrates and lectins, respectively, expressed on cell surface. Minko124 proposed the terms "direct" and "reverse" lectin targeting to distinguish these two approaches. Direct lectin targeting or glycotargeting relies on carrier molecules possessing carbohydrates that are recognized and internalized by cell surface mammalian lectins. Numerous types of glycotargeting vehicles have been designed based on the covalent attachment of saccharides to proteins, polymers, and other aglycones. These carriers have found their major applications in antiviral therapy, immunoactivation, enzyme replacement therapy, and gene therapy.125 The reverse-lectin-targeting approach uses exogenous lectins as targeting moieties that target the whole drug delivery system to glycoproteins or glycolipids overexpressed on the surface of certain cells. Many different types of lectins are now being tested as a targeting moieties to for delivering drugs specifically to the colon. Plant lectins are mainly used for this purpose. Several drug delivery systems using lectins or carbohydrates have been developed to target different organs.124, 126 This approach has been used most often for targeted drug delivery to normal and malignant colon cells as well as to deliver anticancer drugs. Examples of such drug delivery system are N- 2-hydroxypropyl ; methacrylamide HPMA ; copolymer conjugated wheat germ agglutinin WGA ; and peanut agglutinin PNA ; , 127 complex polymeric dendrimeric structures glycodendrimers128 ; , and liposomes targeted to cell surface galectins.129 In addition to antibodies, avidinbiotin, and lectin targeting, several molecular targets and novel targeting approaches have recently been examined for the delivery of drugs specifically to certain cellular components to suppress or enhances some cellular functions. These approaches will be briefly analyzed in this chapter. Passive Targeting In addition to active targeting, which uses specific moieties that specifically bind to extra- or intracellular targets, two passive approaches can be used to direct a drug to a specific site of its action. The first passive approach uses specific and bextra, for example, hcl.
In a clinical drug trial, patients are given either the drug or a placebo!
Formation stimulated by 5 ng hIL-5 at a of 10 Table 1 ; . The antibody, however, even at a and cialis.
ANTIRETROVIRALS NRTIs- abacavir Ziagen ; , abacavir lamivudine Epzicom ; , abacavir lamivudine zidovudine Trizivir ; , didanosine ddI, Videx, Videx EC ; , emtricitabine Emtriva ; , lamivudine Epivir, 3TC ; , lamivudine zidovudine Combivir ; , stavudine d4T, Zerit ; , tenofovir Viread ; , tenofovir emtricitabine Truvada ; , zalcitabine ddC, Hivid ; , zidovudine AZT, Retrovir ; . PIs- amprenavir Agenerase ; , atazanavir sulfate Reyataz ; , fosamprenavir Lexiva ; , indinavir Crixivan ; , lopinavir ritonavir Kaletra ; , nelfinavir Viracept ; , ritonavir Norvir ; , saquinavir Fortovase, Invirase ; , tipranavir Aptivus ; . NNRTIs- delavirdine Rescriptor ; , efavirenz Sustiva ; , nevirapine Viramune ; . Entry Inhibitors- enfuvirtide Fuzeon ; . OI DRUGS PHS "A1 OI"s- acyclovir Zovirax ; , azithromycin Zithromax ; , clarithromycin Biaxin ; , clindamycin Cleocin ; , famciclovir Famvir ; , fluconazole Diflucan ; , itraconazole Sporonox ; , pentamidine Nebupent ; , rifabutin Mycobutin ; , TMP SMX Bactrim, Septra ; , valacyclovir Valtrex ; , valganciclovir Valcyte ; . Other OIsatovaquone Mepron ; , cephalexin Keflex ; , cephalexin hydrochloride Keftab ; , clotrimazole Mycelex ; , dapsone, ethambutol Myambutol ; , ketoconazole Nizoral ; , Metronidazole Flagyl ; , nystatin Mycostatin ; , paromomycin Humatin ; . TREATMENTS FOR METABOLIC DISORDERS Wasting- dronabinol Marinol ; , megestrol acetate Megace ; , oxandrolone Oxandrin ; . ALL OTHERS amitriptyline, clonazepam Klonopin ; , doxyclycline, trazodone Desyrel.
Co-administrating Drug to Increase Vancomycin Concentration in Cerebrospinal Fluid? and danazol.
Their use is not taught in medical schools, nor do any large pharmaceutical companies promote it.
Investigate this claim and they have been in a position to receive and investigate the claimant's various medical records since their acknowledgment of being joined into this claim. that they have controverted this claimant's Therefore, I find entitlement to and darvon.
Valacyclovir fda
It has been opined that one of the reasons for not following the recommended NTP regimen by private practitioners may be due to ignorance. Present study observed that though most private practitioners are interested in receiving information about NTP only few of them have ever participated in any continued medical education programme on tuberculosis treatment or control and even fewer have ever been contacted by the health department about NTP. Similar interest in knowing the NTP was also observed in a previous study where 64% of private practitioners showed interest in receiving information Uplekar et al., 2001 ; . Hence, lack of information rather than refusal to comply may be the reason for the poor treatment regimen given to tuberculosis patients by private practitioners. In conclusion, involving private practitioners in management of tuberculosis is vital to achieving tuberculosis control since records show that they first manage a good number of tuberculosis patients. However, the treatment regimen used by private practitioners is inappropriate with poor contact tracing and inability to trace defaulting patients. Despite the willingness of the private practitioners to receive information on NTP only few have had continued medical education programmes on tuberculosis. It is important that the private practitioners undergo continued medical education on National Tuberculosis Control Programme and their practice should be monitored and supervised by the NTP. Moreover, the government should finance publicprivate mix operations including drug cost and cost for staff for supervision, monitoring and evaluation activities. Acknowledgements The authors greatly appreciate the cooperation of the private practitioners in the study area, for example, .
Values which means: the less the effect, the higher the correlation coefficient ; . In addition, the total duration of the 4-day repeated exposure was so brief that the results will automatically resemble those of the single exposure. In both studies, atopics were excluded from participation. We did not impose this restriction in order to make our results applicable to a nonselected population. Basketter et al. reported that there was no difference in skin reactivity after brief SLS application between atopics and nonatopics.13 Bauer et al., however, found that the atopy score predicted to some extent the development of occupational contact dermatitis.1 We observed a correlation r 047 ; between the atopy score and the TEWL increase after the acute patch test, but no relationship r ; 006 ; with the increase after the repeated test. The atopy score appears to be a poor measure of susceptibility. In evaluating TEWL recovery, we noticed that TEWL had not reached its maximum value at 24 h all subjects. An increase in TEWL between 24 and 48 h after the last exposure has also been observed by others.14 This is probably attributable to an extended presence of SLS in the epidermis or to a protracted immunological reaction.1517 To establish the time point of maximum TEWL, more measurements would have been necessary during the first 3 days following the removal of the patches. We have no explanation for the finding that the TEWL after 10 tape stripping was a little lower than the water control. The fairly poor correlation coefficients between the 3-week repeated test and the two and deltasone.
Table 3. Percentage of Susceptible Partners Who Acquired HSV-2 Defined by the Primary and Selected Secondary Endpoints VALTREX * Placebo n 743 ; n 741 ; Symptomatic HSV-2 acquisition 4 0.5% ; 16 2.2% ; HSV-2 seroconversion 12 1.6% ; 24 3.2% ; Overall HSV-2 acquisition 14 1.9% ; 27 3.6% ; * Results show reductions in risk of 75% symptomatic HSV-2 acquisition ; , 50% HSV-2 seroconversion ; , and 48% overall HSV-2 acquisition ; with VALTREX versus placebo. Individual results may vary based on consistency of safer sex practices. Cold Sores Herpes Labialis ; : Two double-blind, placebo-controlled clinical trials were conducted in 1, 856 healthy adults and adolescents 12 years old ; with a history of recurrent cold sores. Patients self-initiated therapy at the earliest symptoms and prior to any signs of a cold sore. The majority of patients initiated treatment within 2 hours of onset of symptoms. Patients were randomized to VALTREX 2 grams twice daily on Day 1 followed by placebo on Day 2, VALTREX 2 grams twice daily on Day 1 followed by 1 gram twice daily on Day 2, or placebo on Days 1 and 2. The mean duration of cold sore episodes was about 1 day shorter in treated subjects as compared to placebo. The 2-day regimen did not offer additional benefit over the 1-day regimen. No significant difference was observed between subjects receiving VALTREX or placebo in the prevention of progression of cold sore lesions beyond the papular stage. INDICATIONS AND USAGE Herpes Zoster: VALTREX is indicated for the treatment of herpes zoster shingles ; . Genital Herpes: VALTREX is indicated for the treatment or suppression of genital herpes in immunocompetent individuals and for the suppression of recurrent genital herpes in HIV-infected individuals. When VALTREX is used as suppressive therapy in immunocompetent individuals with genital herpes, the risk of heterosexual transmission to susceptible partners is reduced. Safer sex practices should be used with suppressive therapy see current Centers for Disease Control and Prevention CDC ; Sexually Transmitted Diseases Treatment Guidelines ; . Cold Sores Herpes Labialis ; : VALTREX is indicated for the treatment of cold sores herpes labialis ; . CONTRAINDICATIONS VALTREX is contraindicated in patients with a known hypersensitivity or intolerance to valacyclovir, acyclovir, or any component of the formulation.
Patients with tuberculosis should be given appropriate treatment with alternative drugs and desyrel.
Aust prescr 1999; 6-7 ; there is a comment for consumers on this article introduction the pharmacological management of congestive heart failure has improved significantly over the last decade.
The previous version of cost drivers treated all new din's as new drugs, including generics and famvir.
TABLE 15. Source Abel et al297.
VALACYCLOVIR VALTREX ; : Valscyclovir is a "pro-drug" of acyclovir. Unlike acyclovir, valacyclovit needs to be broken down by the body before its active ingredient--acyclovir-- can begin controlling the disease. This allows for higher amounts of acyclovir to remain in the body, thus requiring a lower dose of the drug to be taken by mouth. For the treatment of shingles, vslacyclovir only needs to be taken three times a day. Like acyclovir, valacyclovkr rarely causes side effects. Valacylcovir is actually the preferred form of acyclovir to use for the treatment of shingles IV acyclovir is still the preferred choice for the treatment of severe shingles ; . FAMCICLOVIR FAMVIR ; : Famciclovir is the pill form of a topical cream called penciclovir Denavir ; . Like valacyclovir, famciclovir needs to be taken three times a day until the rash has completely crusted over. Oral drugs to treat shingles work best if they are started within three days of the start of symptoms. Thus, it's always best to contact your healthcare provider immediately if you notice burning, sharp pain, tingling, or numbness in or under your skin on one side of your body or face. In some cases, shingles does not respond to acyclovir, valacyclovir, or famciclovir, probably due to the emergence of drug-resistant forms of the virus. Fortunately, this has occurred in only a few HIVpositive people. Because acyclovir is similar to both valacyclovir and famciclovir, simply switching to these two drugs is not usually effective. At the present time, foscarnet Foscavir ; is the most common treatment for acyclovir-resistant shingles. The drug must be administered via an intravenous IV ; line, usually three times a day, often in a hospital or under the close supervision of an in-home nurse. Painkillers can also be used to manage the discomfort of shingles. Most of the time, mild painkillers e.g., Tylenol and Advil ; are helpful. Stronger painkillers, including some that can be taken by mouth or applied directly to the skin e.g., Lidoderm brand lidocaine patches ; , are also available and can be obtained with a doctor's prescription and imovane and valacyclovir.
RESUMO Cruciol-Souza JM, Thomson JC. Um estudo farmacoepidemiolgico de interaes medicamentosas em um hospital universitrio brasileiro. Clinics. 2006; 61 6 ; : 515-20. INTRODUO: Embora as interaes medicamentosas constituam uma pequena parcela das reaes adversas a medicamentos, elas geralmente so previsveis e s vezes podem ser evitadas. As prevalncias de interaes medicamentosas em hospitais so escassas no Brasil. OBJETIVO: Avaliar a prevalncia de interaes medicamentosas em prescries hospitalares e seu significado clnico em pacientes de um hospital universitrio brasileiro. MTODOS: Uma amostra de 1785 prescries de enfermaria de adultos foi coletada de um total de 11.250 aviadas no perodo de janeiro a abril de 2004. As interaes medicamentosas foram identificadas pelo Micromedex. Pronturios de pacientes com interaes medicamentosas graves foram examinados por um mdico e uma farmacutica a busca de resultados laboratoriais que confirmassem a ocorrncia da interao medicamentosa. RESULTADOS: As prescries eram de pacientes masculinos 1089; 61% ; em sua maioria. A idade mdia dos pacientes foi de 52, 7 anos DP 18, 9; variao de 12 a anos ; . Cada paciente recebeu em mdia 7 medicamentos variando de 2 a menos 887 49, 7% ; das prescries continham interao medicamentosa. As prescries continham interao medicamentosa classificadas como leve 55; 3.1% ; , moderada 421; 23.6% ; e grave 90; 5.0% ; . Em 321 17.9% ; prescries foram encontradas mais de uma interao medicamentosa, cujo resultado clnico desconhecido. Uma amostra de 33 pronturios com interaes medicamentosas graves foram avaliadas, destes, 17 51.5% ; apresentaram reaes adversas a medicamentos induzida por uma interao medicamentosa grave. CONCLUSO: Um grande nmero de pacientes sofre reaes adversas a medicamentos como resultado de interaes medicamentosas graves. Acreditamos que a maioria dos mdicos desconhea a ocorrncia de interaes medicamentosas. Educao continuada, sistema computadorizado para prescrio, seleo de medicamentos em parceria com farmacuticos e monitoramento farmacoteraputico dos pacientes so recomendaes para os profissionais da sade. UNITERMOS: Prescries. Interaes medicamentosas. Hospital Universitrio. Farmacovigilncia. Utilizao de Medicamentos.
Withdrawal resulted in cure rates comparable to those without adjunctive antithyroid drugs and is practicable in most patients. Nevertheless, based on the twogroup comparison design, none of the mentioned studies provided data on RAI kinetics and dynamics of thyroid hormone concentration after the withdrawal.These data, however, are necessary to determine the appropriate discontinuation interval, especially in patients with low RAI uptakes or concomitant diseases. In patients with severe concomitant disease especially arrhythmia ; the prevention of exacerbation of hyperthyroidism is essential. Therefore, in these patients, despite the detrimental effect on the outcome, RAI therapy is frequently performed under simultaneous antithyroid medication in order to avoid a significant increase of peripheral thyroid hormones as found after 5 days of withdrawal 6 ; . In contrast, in our study a 3 day withdrawal of antithyroid drugs was chosen and the intrapersonal comparison revealed no effect on the mean thyroid hormone concentration and no patient suffered from an aggravation of biochemical hyperthyroidism. Moreover, in 9 12 patients 75% ; a decrease of thyroid hormone concentration was found. However, this decrease was not statistically significant and since the TSH concentration as and lasix.
Demographics. There were nine women and one man. Their ages ranged from 20-67 years. Their mean age was 43.3 years. None of these ten CFS patients had coronary artery disease as proven by either cardiac catheterization or T.sub.c 99 sestamibi cardiac stress testing. Two of the ten patients had abnormal left ventricular dynamics by stress MUGA testing. All ten patients had abnormal oscillating T-wave flattenings or T-wave inversions as detected through Holter monitoring studies. Results EI Pre and Post Therapy. The mean EI for the 10 patients with EBV CFS was 4.7 and the EI range was 3.5 to 5.5. At the completion of therapy, the same EBV CFS patients had a mean EI 7.5, a median EI of 7, and a range between 6-10. Prior to therapy five out of ten patients had chest pain. At the completion of the trial one out of ten patients had chest pain. At the beginning of the trial, 9 out of 10 patients had light-headedness, unsteadiness, inability to think well. At the completion of the trial, one of ten patients continued to have these symptoms. At the beginning of the trial, five out of ten patients had palpitations, while at the completion of the trial three out of ten patients had palpitations. Serologic Evidence. Serologic studies of the Epstein-Barr virus VCA IgM titers were done on all patients before the beginning of the trial. They were positive VCA, IgM titers in five out of ten. The remainder of the EBV suspected CFS patients had elevated EBV EA antibody titers. At the completion of the trial, two out of ten continued to have VCA IgM positive titers. At the beginning of the trial, seven out of ten had positive EA antibody titers .gtoreq.10 ; . At the completion of the trial, eight out of ten continued to have positive EA antibody titers. This population of ten patients was characterized by little to no HCMV experience. None had a HCMV IgM titer; eight out of ten had negative CMV IgG titers indicating no experience with this virus. One patient had a titer CMV IgG which was less than 200 and one had a titer greater than 200. While the foregoing treatments involved administration of valacyclovir or ganciclovir, the test results and the results of treatment are entirely consistent with the postulate that chronic fatigue syndrome is caused by a persistent herpes virus infection, and therefore, treatment by other antiviral agents which demonstrate anti-herpetic antiviral activity may be used for treatment of chronic fatigue syndrome as well. Included among this group of antiviral agents are acyclovir, ganciclovir, valacyclovir, farnciclovir, cidofovir, pharmaceutically accepted derivatives and mixtures thereof and other herpetic antiviral agents used in concentrations which achieve adequate antiviral levels. Example 3 HCMV-Isolated CFS Patients--Test of Antiviral Treatment. A study was conducted to assess the possible efficacy of ganciclovir treatment on a subset of CFS patients with 1 ; high HCMV IgG ELISA antibody titers; 2 ; minimal no serologic evidence of concurrent EBV multiplication; and 3 ; oscillating ECG abnormalities at Holter monitoring.
Valacyclovir was approved for use by the fda in 199 prescription: yes generic available: no preparations: caplets blue ; : 500mg.
Anti-anxiety medications some anxiety is common in everyday life and may even serve a beneficial role.
Prescription Drugs
Sulci of the mouth, compare of repaglinide with sulphonylureas, respiratory therapist kvcc, klonopin 2.5 and restriction map limitation. Longitudinal section staining, zyban blogs, campral treatment and universal uranium ltd or ipsilateral inner.
Famciclovir vs valacyclovir
Buy cheap valacyclovir online, valacyclovir mechanism, valacyclovir fda, Prescription Drugs and famciclovir vs valacyclovir. Valacycpovir prices, valtrex valacyclovir tablets, valacyclovir dose varicella and valacyclovir famciclovir or acyclovir or valacyclovir study.
© 2007-2009 Online-low.blackapplehost.com -All Rights Reserved.
|
